Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

@article{Vermersch2014TeriflunomideVS,
  title={Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial},
  author={Patrick Vermersch and Anna Członkowska and Luigi Maria Edoardo Grimaldi and Christian Confavreux and Giancarlo Comi and Ludwig Kappos and Tomas P. Olsson and Myriam B{\'e}namor and Deborah R Bauer and Philippe Truffinet and Meg Church and Aaron E Miller and Jerry S. Wolinsky and Mark S. Freedman and P. W. O'Connor},
  journal={Multiple Sclerosis Journal},
  year={2014},
  volume={20},
  pages={705 - 716}
}
Background: In previous studies, teriflunomide significantly reduced the annualised relapse rate (ARR) and disability progression. Objective: This phase 3, rater-blinded study (NCT00883337) compared teriflunomide with interferon-beta-1a (IFNβ-1a). Methods: Patients with relapsing multiple sclerosis were randomised (1:1:1) to oral teriflunomide 7-or 14mg, or subcutaneous IFNβ-1a 44µg. The primary composite endpoint was time to failure, defined as first occurrence of confirmed relapse or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 104 CITATIONS, ESTIMATED 59% COVERAGE

Teriflunomide: A Review in Relapsing–Remitting Multiple Sclerosis

VIEW 14 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Immunological Aspects of Approved MS Therapeutics

  • Front. Immunol.
  • 2019
VIEW 15 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Optimizing therapy early in multiple sclerosis: An evidence-based view.

  • Multiple sclerosis and related disorders
  • 2015
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2014
2020

CITATION STATISTICS

  • 16 Highly Influenced Citations

  • Averaged 17 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

Genzyme presents second phase III study of once-daily oral Aubagio (teriflunomide) confirming significant impact on disability

Press Release
  • Available at: http://www. marketwatch.com/story/genzyme-presents-second-phase-iiistudy-of-once-daily-oral-aubagior-teriflunomide-confirmingsignificant-impact-on-disability-2012–10–12
  • 2013

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells (P938)

L Li, J Liu, G Ringheim
  • Mult Scler
  • 2011